Sialic acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated mitochondrial perturbation in Jurkat cells

Tatsuta,Takeo; Hosono,Masahiro; Sugawara,Shigeki; Kariya,Yukiko; Ogawa,Yukiko; Hakomori,Senitiroh; Nitta,Kazuo

doi:10.3892/ijo.2013.2092

Sialic acid-binding lectin (leczyme) induces caspase-dependent apoptosis-mediated mitochondrial perturbation in Jurkat cells

Authors:
- Takeo Tatsuta
- Masahiro Hosono
- Shigeki Sugawara
- Yukiko Kariya
- Yukiko Ogawa
- Senitiroh Hakomori
- Kazuo Nitta
View Affiliations

Affiliations: Division of Cell Recognition Study, Institute of Molecular Biomembrane and Glycobiology, Tohoku Pharmaceutical University, Aoba-ku, Sendai 981-8558, Japan, Fukushima Medical University, Fukushima 960-1295, Japan, Divisions of Functional Morphology and Microbiology, Department of Pharmacy, Faculty of Pharmaceutical Science, Nagasaki International University, Sasebo, Nagasaki 859-3298, Japan, Division of Biomembrane Research, Pacific Northwest Research Institute, Seattle, WA 98122, USA
Published online on: September 5, 2013 https://doi.org/10.3892/ijo.2013.2092
Pages: 1402-1412
Copyright: © Tatsuta et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sialic acid binding lectin (SBL) isolated from Rana catesbeiana oocytes is a multifunctional protein which has lectin activity, ribonuclease activity and antitumor activity. However, the mechanism of antitumor effects of SBL is unclear to date and the validity for human leukemia cells has not been fully studied. We report here that SBL shows cytotoxicity for some human leukemia cell lines including multidrug-resistant (MDR) cells. The precise mechanisms of SBL-induced apoptotic signals were analyzed by combinational usage of specific caspase inhibitors and the mitochondrial membrane depolarization detector JC-1. It was demonstrated that SBL causes mitochondrial perturbation and the apoptotic signal is amplified by caspases and cell death is executed in a caspase-dependent manner. The efficacy of this combinational usage was shown for the first time, to distinguish the apoptotic pathway in detail. SBL selectively kills tumor cells, is able to exhibit cytotoxicity regardless of P-glycoprotein expression and has potential as an alternative to conventional DNA-damaging anticancer drugs.

View Figures

View References

1.	Costanzi J, Sidransky D, Navon A and Goldsweig H: Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest. 23:643–650. 2005. View Article : Google Scholar : PubMed/NCBI
2.	Deshpande RA and Shankar V: Ribonucleases from T2 family. Crit Rev Microbiol. 28:79–122. 2002. View Article : Google Scholar : PubMed/NCBI
3.	Fang EF, Zhang CZ, Fong WP and Ng TB: RNase MC2: a new Momordica charantia ribonuclease that induces apoptosis in breast cancer cells associated with activation of MAPKs and induction of caspase pathways. Apoptosis. 17:377–387. 2012.
4.	D’Alessio G: New and cryptic biological messages from RNases. Trends Cell Biol. 3:106–109. 1993.PubMed/NCBI
5.	Raines RT: Ribonuclease A. Chem Rev. 98:1045–1066. 1998. View Article : Google Scholar
6.	Ita M, Halicka HD, Tanaka T, Kurose A, Ardelt B, Shogen K and Darzynkiewicz Z: Remarkable enhancement of cytotoxicity of onconase and cepharanthine when used in combination on various tumor cell lines. Cancer Biol Ther. 7:1104–1108. 2008. View Article : Google Scholar : PubMed/NCBI
7.	Rybak SM, Pearson JW, Fogler WE, Volker K, Spence SE, Newton DL, Mikulski SM, Ardelt W, Riggs CW, Kung HF and Longo DL: Enhancement of vincristine cytotoxicity in drug-resistant cells by simultaneous treatment with onconase, an antitumor ribonuclease. J Natl Cancer Inst. 88:747–753. 1996. View Article : Google Scholar : PubMed/NCBI
8.	Kim DH, Kim EJ, Kalota A, Gewirtz AM, Glickson J, Shogen K and Lee I: Possible mechanisms of improved radiation response by cytotoxic RNase, Onconase, on A549 human lung cancer xenografts of nude mice. Adv Exp Med Biol. 599:53–59. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Halicka HD, Murakami T, Papageorgio CN, Mittelman A, Mikulski SM, Shogen K and Darzynkiewicz Z: Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase. Cell Prolif. 33:407–417. 2000. View Article : Google Scholar : PubMed/NCBI
10.	Tsai SY, Hsieh TC, Ardelt B, Darzynkiewicz Z and Wu JM: Combined effects of onconase and IFN-beta on proliferation, macromolecular syntheses and expression of STAT-1 in JCA-1 cancer cells. Int J Oncol. 20:891–896. 2002.PubMed/NCBI
11.	Mikulski SM, Viera A, Darzynkiewicz Z and Shogen K: Synergism between a novel amphibian oocyte ribonuclease And lovastatin in inducing cytostatic and cytotoxic effects in human lung and pancreatic carcinoma cell lines. Br J Cancer. 66:304–310. 1992. View Article : Google Scholar
12.	Rutkoski TJ, Kink JA, Strong LE, Schilling CI and Raines RT: Antitumor activity of ribonuclease multimers created by site-specific covalent tethering. Bioconjug Chem. 21:1691–1702. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Haigis MC, Kurten EL and Raines RT: Ribonuclease inhibitor as an intracellular sentry. Nucleic Acids Res. 31:1024–1032. 2003. View Article : Google Scholar : PubMed/NCBI
14.	Ledoux L and Brachet J: Remarks on preparations of ribonuclease from different manufacturing sources. Biochim Biophys Acta. 16:2901955.PubMed/NCBI
15.	Ledoux L: Action of ribonuclease on neoplastic growth. II. Action on Landschutz ascites cells in vitro. Biochim Biophys Acta. 20:369–377. 1956. View Article : Google Scholar : PubMed/NCBI
16.	Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ and Shogen K: Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet. 21:169–182. 1988.PubMed/NCBI
17.	Easty DM, Ledoux L and Ambrose EJ: The action of ribonuclease on neoplastic growth. III. Studies by interference microscopy. Biochim Biophys Acta. 20:528–537. 1956. View Article : Google Scholar : PubMed/NCBI
18.	Telford IR, Kemp JF, Taylor EF and Yeaman MW: Effect of ribonuclease on survival of ascites tumor bearing mice. Proc Soc Exp Biol Med. 100:829–831. 1959. View Article : Google Scholar : PubMed/NCBI
19.	Ledoux L: Action of ribonuclease on two solid tumours in vivo. Nature. 176:36–37. 1955. View Article : Google Scholar : PubMed/NCBI
20.	Ardelt W, Mikulski SM and Shogen K: Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem. 266:245–251. 1991.PubMed/NCBI
21.	Ledoux L and Revell SH: Action of ribonuclease on neoplastic growth. I. Chemical aspects of normal tumour growth: the Landschutz ascites tumour. Biochim Biophys Acta. 18:416–426. 1955.PubMed/NCBI
22.	Aleksandrowicz J, Urbanczyk J, Ostrowska A and Sierko J: Further research on the activity of ribonucleases in the blood and urine of patients suffering from proliferative hemocytopathia. Blood. 13:652–664. 1958.PubMed/NCBI
23.	Vert A, Castro J, Ruiz-Martinez S, Tubert P, Escribano D, Ribo M, Vilanova M and Benito A: Generation of new cytotoxic human ribonuclease variants directed to the nucleus. Mol Pharm. 9:2894–2902. 2012. View Article : Google Scholar : PubMed/NCBI
24.	Fang EF and Ng TB: Ribonucleases of different origins with a wide spectrum of medicinal applications. Biochim Biophys Acta. 1815:65–74. 2011.PubMed/NCBI
25.	Castro J, Ribo M, Navarro S, Nogues MV, Vilanova M and Benito A: A human ribonuclease induces apoptosis associated with p21WAF1/CIP1 induction and JNK inactivation. BMC Cancer. 11:92011. View Article : Google Scholar : PubMed/NCBI
26.	Kawauchi H, Sakakibara F and Watanabe K: Agglutinins of frog eggs: a new class of proteins causing preferential agglutination of tumor cells. Experientia. 31:364–365. 1975. View Article : Google Scholar : PubMed/NCBI
27.	Sakakibara F, Kawauchi H, Takayanagi G and Ise H: Egg lectin of Rana japonica and its receptor glycoprotein of Ehrlich tumor cells. Cancer Res. 39:1347–1352. 1979.
28.	Nitta K, Takayanagi G, Kawauchi H and Hakomori S: Isolation and characterization of Rana catesbeiana lectin and demonstration of the lectin-binding glycoprotein of rodent and human tumor cell membranes. Cancer Res. 47:4877–4883. 1987.PubMed/NCBI
29.	Titani K, Takio K, Kuwada M, Nitta K, Sakakibara F, Kawauchi H, Takayanagi G and Hakomori S: Amino acid sequence of sialic acid binding lectin from frog (Rana catesbeiana) eggs. Biochemistry. 26:2189–2194. 1987. View Article : Google Scholar : PubMed/NCBI
30.	Kamiya Y, Oyama F, Oyama R, Sakakibara F, Nitta K, Kawauchi H, Takayanagi Y and Titani K: Amino acid sequence of a lectin from Japanese frog (Rana japonica) eggs. J Biochem. 108:139–143. 1990.PubMed/NCBI
31.	Nitta K, Oyama F, Oyama R, Sekiguchi K, Kawauchi H, Takayanagi Y, Hakomori S and Titani K: Ribonuclease activity of sialic acid-binding lectin from Rana catesbeiana eggs. Glycobiology. 3:37–45. 1993. View Article : Google Scholar : PubMed/NCBI
32.	Okabe Y, Katayama N, Iwama M, Watanabe H, Ohgi K, Irie M, Nitta K, Kawauchi H, Takayanagi Y, Oyama F, et al: Comparative base specificity, stability, and lectin activity of two lectins from eggs of Rana catesbeiana and R. japonica and liver ribonuclease from R catesbeiana. J Biochem. 109:786–790. 1991.PubMed/NCBI
33.	Nitta K, Ozaki K, Ishikawa M, Furusawa S, Hosono M, Kawauchi H, Sasaki K, Takayanagi Y, Tsuiki S and Hakomori S: Inhibition of cell proliferation by Rana catesbeiana and Rana japonica lectins belonging to the ribonuclease superfamily. Cancer Res. 54:920–927. 1994.PubMed/NCBI
34.	Nitta K, Ozaki K, Tsukamoto Y, Furusawa S, Ohkubo Y, Takimoto H, Murata R, Hosono M, Hikichi N, Sasaki K, et al: Characterization of a Rana catesbeiana lectin-resistant mutant of leukemia P388 cells. Cancer Res. 54:928–934. 1994.
35.	Nitta K, Ozaki K, Tsukamoto Y, Hosono M, Ogawakonno Y, Kawauchi H, Takayanagi Y, Tsuiki S and Hakomori S: Catalytic lectin (leczyme) from bullfrog (Rana catesbeiana) eggs. Int J Oncol. 9:19–23. 1996.PubMed/NCBI
36.	Liao YD: A pyrimidine-guanine sequence-specific ribonuclease from Rana catesbeiana (bullfrog) oocytes. Nucleic Acids Res. 20:1371–1377. 1992. View Article : Google Scholar : PubMed/NCBI
37.	Liao YD, Huang HC, Leu YJ, Wei CW, Tang PC and Wang SC: Purification and cloning of cytotoxic ribonucleases from Rana catesbeiana (bullfrog). Nucleic Acids Res. 28:4097–4104. 2000. View Article : Google Scholar : PubMed/NCBI
38.	Tang CH, Hu CC, Wei CW and Wang JJ: Synergism of Rana catesbeiana ribonuclease And IFN-gamma triggers distinct death machineries in different human cancer cells. FEBS Lett. 579:265–270. 2005.PubMed/NCBI
39.	Ishiyama M, Miyazono Y, Sasamoto K, Ohkura Y and Ueno K: A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta. 44:1299–1305. 1997. View Article : Google Scholar : PubMed/NCBI
40.	Liao YD, Huang HC, Chan HJ and Kuo SJ: Large-scale preparation of a ribonuclease from Rana catesbeiana (bullfrog) oocytes and characterization of its specific cytotoxic activity against tumor cells. Protein Expr Purif. 7:194–202. 1996.PubMed/NCBI
41.	Hu CC, Lee YH, Tang CH, Cheng JT and Wang JJ: Synergistic cytotoxicity of Rana catesbeiana ribonuclease And IFN-gamma on hepatoma cells. Biochem Biophys Res Commun. 280:1229–1236. 2001.PubMed/NCBI
42.	Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control. 10:159–165. 2003.PubMed/NCBI
43.	Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I and Gottesman MM: Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 39:361–398. 1999. View Article : Google Scholar : PubMed/NCBI
44.	Krishna R and Mayer LD: Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283. 2000.PubMed/NCBI
45.	Stavrovskaya AA: Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry (Mosc). 65:95–106. 2000.PubMed/NCBI
46.	Ozben T: Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett. 580:2903–2909. 2006. View Article : Google Scholar : PubMed/NCBI
47.	Castro J, Ribo M, Puig T, Colomer R, Vilanova M and Benito A: A cytotoxic ribonuclease reduces the expression level of P-glycoprotein in multidrug-resistant cell lines. Invest New Drugs. 30:880–888. 2012. View Article : Google Scholar : PubMed/NCBI
48.	Elmore S: Apoptosis: a review of programmed cell death. Toxicol Pathol. 35:495–516. 2007. View Article : Google Scholar : PubMed/NCBI
49.	Grutter MG: Caspases: key players in programmed cell death. Curr Opin Struct Biol. 10:649–655. 2000. View Article : Google Scholar : PubMed/NCBI
50.	Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, Siddik ZH, Mills GB and Claret FX: Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem. 278:19245–19256. 2003. View Article : Google Scholar : PubMed/NCBI
51.	Bunyard P, Handley M, Pollara G, Rutault K, Wood I, Chaudry M, Alderman C, Foreman J, Katz DR and Chain BM: Ribotoxic stress activates p38 and JNK kinases and modulates the antigen-presenting activity of dendritic cells. Mol Immunol. 39:815–827. 2003. View Article : Google Scholar : PubMed/NCBI
52.	He K, Zhou HR and Pestka JJ: Mechanisms for ribotoxin-induced ribosomal RNA cleavage. Toxicol Appl Pharmacol. 265:10–18. 2012. View Article : Google Scholar : PubMed/NCBI
53.	Iordanov MS, Wong J, Newton DL, Rybak SM, Bright RK, Flavell RA, Davis RJ and Magun BE: Differential requirement for the stress-activated protein kinase/c-Jun NH(2)-terminal kinase in RNA damage-induced apoptosis in primary and in immortalized fibroblasts. Mol Cell Biol Res Commun. 4:122–128. 2000. View Article : Google Scholar
54.	Fang EF, Zhang CZ, Zhang L, Fong WP and Ng TB: In vitro and in vivo anticarcinogenic effects of RNase MC2, a ribonuclease isolated from dietary bitter gourd, toward human liver cancer cells. Int J Biochem Cell Biol. 44:1351–1360. 2012. View Article : Google Scholar : PubMed/NCBI
55.	Dasmahapatra G, Lembersky D, Kramer L, Fisher RI, Friedberg J, Dent P and Grant S: The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood. 115:4478–4487. 2010. View Article : Google Scholar : PubMed/NCBI
56.	Chen J, Rusnak M, Luedtke RR and Sidhu A: D1 dopamine receptor mediates dopamine-induced cytotoxicity via the ERK signal cascade. J Biol Chem. 279:39317–39330. 2004. View Article : Google Scholar : PubMed/NCBI
57.	Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G and Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
58.	Wolf BB and Green DR: Suicidal tendencies: apoptotic cell death by caspase family proteinases. J Biol Chem. 274:20049–20052. 1999. View Article : Google Scholar : PubMed/NCBI
59.	Kuwana T, Smith JJ, Muzio M, Dixit V, Newmeyer DD and Kornbluth S: Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem. 273:16589–16594. 1998. View Article : Google Scholar : PubMed/NCBI
60.	Li H, Zhu H, Xu CJ and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:491–501. 1998. View Article : Google Scholar : PubMed/NCBI
61.	Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell. 94:481–490. 1998. View Article : Google Scholar : PubMed/NCBI
62.	Schendel SL, Azimov R, Pawlowski K, Godzik A, Kagan BL and Reed JC: Ion channel activity of the BH3 only Bcl-2 family member, BID. J Biol Chem. 274:21932–21936. 1999. View Article : Google Scholar : PubMed/NCBI
63.	Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 292:727–730. 2001. View Article : Google Scholar : PubMed/NCBI
64.	Viswanath V, Wu Y, Boonplueang R, Chen S, Stevenson FF, Yantiri F, Yang L, Beal MF and Andersen JK: Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson’s disease. J Neurosci. 21:9519–9528. 2001.PubMed/NCBI